Multiple Myeloma Clinical Trials

Multiple Myeloma Clinical Trials

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2)

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2)   Sponsor and Collaborators Bristol-Myers Squibb Abbott BiotherapeuticsContinue Reading ClinicalTrials.gov Identifier NCT01239797 

Clinical Trial: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1)

Clinical Trial: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1) Sponsor and Collaborators Bristol-Myers SquibbAbbott Biotherapeutics ClinicalTrials.gov IdentifierContinue Reading NCT01335399

Next post in Multiple Myeloma Clinical Trials